fludarabine has been researched along with Dyskeratosis Congenita, X-Linked in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| DiNardo, C; Gibson, A; Khazal, S; Mahadeo, KM; Petropoulos, D; Ragoonanan, D; Rodriguez, N; Tewari, P | 1 |
| Accornero, E; Algeri, M; Baio, A; Comoli, P; Corbella, F; Cugno, C; Del Fante, C; Giorgiani, G; Gurrado, A; Perotti, C; Pession, A; Strocchio, L; Zecca, M | 1 |
| Chen, J; Ding, L; Li, B; Li, Q; Luo, C; Wang, J | 1 |
| Brown, M; Myers, D; Radhi, M; Rahmetullah, R; Shreve, N | 1 |
| Alter, BP; Baker, KS; Dietz, AC; Giller, RH; Orchard, PJ; Savage, SA; Tolar, J | 1 |
| Dan, K; Yamaguchi, H | 1 |
| Arnold, R; Dokal, I; Dörken, B; Hemmati, PG; le Coutre, P; Neuburger, S; Terwey, TH; Vulliamy, T; Vuong, LG | 1 |
| Bacigalupo, A; Bazarbachi, A; Geara, F; Kharfan-Dabaja, MA; Mahfouz, RA; Otrock, ZK | 1 |
| Canazzio, A; De Stefano, P; Giorgiani, G; Locatelli, F; Nobili, B; Perrotta, S; Rossi, G; Zecca, M | 1 |
| Calixto, R; Domingues, MC; Florêncio, R; Ostronoff, F; Ostronoff, M; Souto Maior, AP; Sucupira, A; Tagliari, C | 1 |
| Amarasinghe, K; Dalley, C; Dokal, I; Gupta, V; Laurie, A; Marsh, J | 1 |
1 review(s) available for fludarabine and Dyskeratosis Congenita, X-Linked
| Article | Year |
|---|---|
[Bone marrow failure due to telomere associated gene mutation].
Topics: Animals; Cell Cycle Proteins; Dyskeratosis Congenita; Genes, Dominant; Genes, Recessive; Genes, X-Linked; Hematopoietic Stem Cell Transplantation; Humans; Mice; Mutation; Nuclear Proteins; Oxymetholone; RNA; Telomerase; Telomere; Telomere-Binding Proteins; Transplantation Conditioning; Vidarabine | 2010 |
1 trial(s) available for fludarabine and Dyskeratosis Congenita, X-Linked
| Article | Year |
|---|---|
Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child, Preschool; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Dyskeratosis Congenita; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Peripheral Blood Stem Cell Transplantation; Pulmonary Fibrosis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2011 |
9 other study(ies) available for fludarabine and Dyskeratosis Congenita, X-Linked
| Article | Year |
|---|---|
Non-myeloablative umbilical cord blood transplantation for atypical dyskeratosis congenita.
Topics: Alemtuzumab; Antineoplastic Agents; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Dyskeratosis Congenita; Female; Germ-Line Mutation; Humans; Mismatch Repair Endonuclease PMS2; Vidarabine; Whole-Body Irradiation | 2022 |
Successful T-cell-depleted haploidentical hematopoietic stem cell transplantation in a child with dyskeratosis congenita after a fludarabine-based conditioning regimen.
Topics: Child; Dyskeratosis Congenita; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Depletion; Male; T-Lymphocytes; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2015 |
[Molecular diagnosis and hematopoietic stem cell transplantation in 17 children with inherited bone marrow failure syndrome].
Topics: Anemia, Aplastic; Anemia, Diamond-Blackfan; Bone Marrow Diseases; Bone Marrow Failure Disorders; Child; Dyskeratosis Congenita; Fanconi Anemia; Fetal Blood; Hematopoietic Stem Cell Transplantation; Hemoglobinuria, Paroxysmal; Humans; Retrospective Studies; Siblings; Survival Rate; Transplantation Conditioning; Unrelated Donors; Vidarabine | 2015 |
Reduced intensity conditioning regimen with fludarabine, cyclophosphamide, low dose TBI and alemtuzumab leading to successful unrelated umbilical cord stem cell engraftment and survival in two children with dyskeratosis congenita.
Topics: Alemtuzumab; Bone Marrow; Child; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Dyskeratosis Congenita; Graft Survival; Hematopoietic Stem Cell Transplantation; Heterozygote; Humans; Immunosuppressive Agents; Male; Mutation; Transplantation Conditioning; Vidarabine; Whole Body Imaging | 2016 |
Reduced-intensity conditioning using fludarabine and antithymocyte globulin alone allows stable engraftment in a patient with dyskeratosis congenita.
Topics: Antilymphocyte Serum; Cyclosporine; Dyskeratosis Congenita; Graft Rejection; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Injections, Intravenous; Male; Mycophenolic Acid; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2010 |
A reduced intensity conditioning regimen of fludarabine, cyclophosphamide, antithymocyte globulin, plus 2 Gy TBI facilitates successful hematopoietic cell engraftment in an adult with dyskeratosis congenita.
Topics: Adult; Antilymphocyte Serum; Combined Modality Therapy; Cyclophosphamide; Dyskeratosis Congenita; Hematopoietic Stem Cell Transplantation; Humans; Male; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2012 |
Successful umbilical cord blood transplantation in a child with dyskeratosis congenita after a fludarabine-based reduced-intensity conditioning regimen.
Topics: Antimetabolites; Child, Preschool; Cord Blood Stem Cell Transplantation; Dyskeratosis Congenita; Humans; Male; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2002 |
Fludarabine, cyclophosphamide, and antithymocyte globulin for a patient with dyskeratosis congenita and severe bone marrow failure.
Topics: Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Child, Preschool; Cyclophosphamide; Dyskeratosis Congenita; Female; Humans; Vidarabine | 2007 |
Late death after unrelated-BMT for dyskeratosis congenita following conditioning with alemtuzumab, fludarabine and melphalan.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Bone Marrow Transplantation; Child; Dyskeratosis Congenita; Fatal Outcome; Gastrointestinal Hemorrhage; Humans; Male; Transplantation Conditioning; Vidarabine | 2007 |